Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine

Richard Macdonell, Guy Nagels, David-Axel Laplaud, Carlo Pozzilli, Brigit de Jong, Ana Martins da Silva, Richard Nicholas, Jeannette Lechner-Scott, Julia A Gaebler, Sonalee Agarwal, Ping Wang, Michael Yeh, Maria Hovenden, Per Soelberg Sørensen

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

BACKGROUND: Multiple sclerosis (MS) is a debilitating disease that negatively impacts patients' lives.

OBJECTIVE: ENABLE assessed the effect of long-term prolonged-release (PR) fampridine (dalfampridine extended release in the United States) treatment on patient-perceived health impact in patients with MS with walking impairment.

METHODS: ENABLE was a 48-week, open-label, Phase 4 study of PR-fampridine 10 mg twice daily. Patients who showed any improvement in Timed 25-Foot Walk walking speed at weeks 2 and 4 and any improvement in 12-item MS Walking Scale score at week 4 remained on treatment. The primary endpoint was change from baseline in 36-Item Short-Form Health Survey (SF-36) physical component summary (PCS) score.

RESULTS: At week 4, 707/901 (78.5%) patients met the criteria to remain on treatment. Patients on treatment demonstrated significant and clinically meaningful improvements in SF-36 PCS scores from baseline (mean change (95% confidence interval)) to week 12 (4.30 (3.83, 4.78); p < 0.0001), week 24 (3.75 (3.23, 4.27); p < 0.0001), week 36 (3.46 (2.95, 3.97); p < 0.0001), and week 48 (3.24 (2.72, 3.77); p < 0.0001). Significant improvements from baseline were also demonstrated in secondary health measures in patients on treatment.

CONCLUSION: PR-fampridine improved patient-perceived physical and psychological health impact of MS measured in a real-life setting.

Original languageEnglish
Pages (from-to)944-954
JournalMultiple Sclerosis
Volume22
Issue number7
Early online date7 Oct 2015
DOIs
Publication statusPublished - Jun 2016

Fingerprint Dive into the research topics of 'Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine'. Together they form a unique fingerprint.

Cite this